CO2022014134A2 - N-cianopirrolidinas con actividad como inhibidores de usp30 - Google Patents

N-cianopirrolidinas con actividad como inhibidores de usp30

Info

Publication number
CO2022014134A2
CO2022014134A2 CONC2022/0014134A CO2022014134A CO2022014134A2 CO 2022014134 A2 CO2022014134 A2 CO 2022014134A2 CO 2022014134 A CO2022014134 A CO 2022014134A CO 2022014134 A2 CO2022014134 A2 CO 2022014134A2
Authority
CO
Colombia
Prior art keywords
cyanopyrrolidines
activity
usp30
inhibitors
usp30 inhibitors
Prior art date
Application number
CONC2022/0014134A
Other languages
English (en)
Inventor
Christopher Andrew Luckhurst
Mark Ian Kemp
Paul William Thompson
Original Assignee
Mission Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2005250.2A external-priority patent/GB202005250D0/en
Priority claimed from GBGB2016607.0A external-priority patent/GB202016607D0/en
Application filed by Mission Therapeutics Ltd filed Critical Mission Therapeutics Ltd
Publication of CO2022014134A2 publication Critical patent/CO2022014134A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se relaciona con una clase de N-cianopirrolidinas con actividad como inhibidores de la enzima desubiquitilante USP30, que tiene utilidad en una variedad de áreas terapéuticas, incluyendo condiciones que involucran disfunción mitocondrial, cáncer y fibrosis:
CONC2022/0014134A 2020-04-08 2022-09-30 N-cianopirrolidinas con actividad como inhibidores de usp30 CO2022014134A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2005250.2A GB202005250D0 (en) 2020-04-08 2020-04-08 Novel compounds
GBGB2016607.0A GB202016607D0 (en) 2020-10-20 2020-10-20 Novel Compounds
PCT/EP2021/059032 WO2021204856A1 (en) 2020-04-08 2021-04-07 N-cyanopyrrolidines with activity as usp30 inhibitors

Publications (1)

Publication Number Publication Date
CO2022014134A2 true CO2022014134A2 (es) 2022-10-31

Family

ID=75441909

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0014134A CO2022014134A2 (es) 2020-04-08 2022-09-30 N-cianopirrolidinas con actividad como inhibidores de usp30

Country Status (13)

Country Link
US (1) US20230119013A1 (es)
EP (1) EP4132925A1 (es)
JP (1) JP2023520727A (es)
KR (1) KR20230006487A (es)
CN (1) CN115461340A (es)
AU (1) AU2021253617A1 (es)
BR (1) BR112022020058A2 (es)
CA (1) CA3171349A1 (es)
CO (1) CO2022014134A2 (es)
IL (1) IL296998A (es)
MX (1) MX2022012578A (es)
WO (1) WO2021204856A1 (es)
ZA (1) ZA202212137B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202016800D0 (en) 2020-10-22 2020-12-09 Mission Therapeutics Ltd Novel compounds
EP4441044A1 (en) 2021-12-01 2024-10-09 Mission Therapeutics Limited Substituted n-cyanopyrrolidines with activity as usp30 inhibitors
CN117887844B (zh) * 2023-12-28 2024-08-23 中山大学附属第一医院 Usp20在肝癌放疗增敏中的应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2001077073A1 (en) 2000-04-06 2001-10-18 Merck Frosst Canada & Co. Cathepsin cysteine protease inhibitors
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
BRPI0709950A2 (pt) 2006-04-13 2011-08-02 Actelion Pharmaceuticals Ltd uso de bosentan na preparação de um medicamento para o tratamento de fibrose pulmonar idiopática em estágio precoce e uso de antagonista do receptor endotelin
WO2008151183A1 (en) 2007-06-04 2008-12-11 Avila Therapeutics, Inc. Heterocyclic compounds and uses thereof
TW200922556A (en) 2007-08-20 2009-06-01 Glaxo Group Ltd Novel cathepsin C inhibitors and their use
WO2009129370A1 (en) 2008-04-18 2009-10-22 Glaxo Group Limited Cathepsin c inhibitors
US20090264499A1 (en) 2008-04-18 2009-10-22 Jianghe Deng Cathepsin C Inhibitors
AR071369A1 (es) 2008-04-18 2010-06-16 Glaxo Group Ltd Compuesto de 1- ciano-3-pirrolidinil-n-sustituido-sulfonamida, su uso para preparar un medicamento util para tratar una enfermedad pulmonar obstructiva cronica y composicion farmaceutica que lo comprende
US20120309820A1 (en) 2011-06-04 2012-12-06 Jb Therapeutics Inc. Methods of treating fibrotic diseases using tetrahydrocannabinol-11-oic acids
EP2565186A1 (en) 2011-09-02 2013-03-06 Hybrigenics S.A. Selective and reversible inhibitors of ubiquitin specific protease 7
LT3049417T (lt) 2013-07-31 2019-02-11 Merck Patent Gmbh Piridinai, pirimidnai ir pirazinai kaip btk inhibitoriai ir jų panaudojimas
EP3145505A4 (en) 2014-05-19 2018-02-28 Northeastern University N-acylethanolamine hydrolyzing acid amidase (naaa) inhibitors and their use thereof
EP3148572A4 (en) 2014-05-27 2017-12-27 Pharmakea, Inc. Compositions and methods of delivery of deubiquitinase inhibitors
WO2016019237A2 (en) 2014-07-31 2016-02-04 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
GB201416754D0 (en) 2014-09-23 2014-11-05 Mission Therapeutics Ltd Novel compounds
EP3277677B9 (en) 2015-03-30 2021-07-14 Mission Therapeutics Limited 1-cyano-pyrrolidine compounds as usp30 inhibitors
CN107849013B (zh) 2015-07-14 2022-03-29 特殊治疗有限公司 作为dub抑制剂用于治疗癌症的氰基吡咯烷类
GB201521109D0 (en) 2015-11-30 2016-01-13 Mission Therapeutics Ltd Novel compounds
GB201522267D0 (en) 2015-12-17 2016-02-03 Mission Therapeutics Ltd Novel compounds
GB201522768D0 (en) 2015-12-23 2016-02-03 Mission Therapeutics Ltd Novel compounds
GB201602854D0 (en) 2016-02-18 2016-04-06 Mission Therapeutics Ltd Novel compounds
GB201603779D0 (en) 2016-03-04 2016-04-20 Mission Therapeutics Ltd Novel compounds
GB201604638D0 (en) 2016-03-18 2016-05-04 Mission Therapeutics Ltd Novel compounds
GB201604647D0 (en) 2016-03-18 2016-05-04 Mission Therapeutics Ltd Novel compounds
WO2017163078A1 (en) 2016-03-24 2017-09-28 Mission Therapeutics Limited 1-cyano-pyrrolidine derivatives as dbu inhibitors
US11014912B2 (en) 2016-09-27 2021-05-25 Mission Therapeutics Limited Cyanopyrrolidine derivatives with activity as inhibitors of USP30
GB201616511D0 (en) 2016-09-29 2016-11-16 Mission Therapeutics Limited Novel compounds
GB201616627D0 (en) 2016-09-30 2016-11-16 Mission Therapeutics Limited Novel compounds
TWI771327B (zh) 2016-10-05 2022-07-21 英商使命醫療公司 新穎化合物
WO2018213150A1 (en) 2017-05-15 2018-11-22 Mitobridge, Inc. Usp30 inhibitors
GB201708652D0 (en) 2017-05-31 2017-07-12 Mission Therapeutics Ltd Novel compounds and uses
GB2563595B (en) 2017-06-19 2020-04-15 Edwards Ltd Twin-shaft pumps
IL272838B2 (en) 2017-10-06 2023-09-01 Forma Therapeutics Inc Peptidase-specific ubiquitin inhibition 30
GB2571731A (en) 2018-03-06 2019-09-11 Mission Therapeutics Ltd Novel compounds and uses
SG11202011299PA (en) 2018-05-17 2020-12-30 Forma Therapeutics Inc Fused bicyclic compounds useful as ubiquitin-specific peptidase 30 inhibitors
EP3837262A1 (en) 2018-08-14 2021-06-23 Amgen Inc. N-cyano-7-azanorbornane derivatives and uses thereof
PE20211053A1 (es) 2018-10-05 2021-06-07 Forma Therapeutics Inc Inhibicion de la proteasa 30 especifica de la ubiquitina (usp30)
GB201905375D0 (en) 2019-04-16 2019-05-29 Mission Therapeutics Ltd Novel compounds
GB201905371D0 (en) 2019-04-16 2019-05-29 Mission Therapeutics Ltd Novel compounds
GB201912674D0 (en) 2019-09-04 2019-10-16 Mission Therapeutics Ltd Novel compounds

Also Published As

Publication number Publication date
EP4132925A1 (en) 2023-02-15
MX2022012578A (es) 2022-11-07
IL296998A (en) 2022-12-01
CA3171349A1 (en) 2021-10-14
CN115461340A (zh) 2022-12-09
BR112022020058A2 (pt) 2022-11-22
US20230119013A1 (en) 2023-04-20
AU2021253617A1 (en) 2022-12-01
WO2021204856A1 (en) 2021-10-14
KR20230006487A (ko) 2023-01-10
ZA202212137B (en) 2024-07-31
JP2023520727A (ja) 2023-05-18

Similar Documents

Publication Publication Date Title
CO2022003608A2 (es) Cianopirrolidinas sustituidas con actividad como inhibidores de usp30
CO2022014134A2 (es) N-cianopirrolidinas con actividad como inhibidores de usp30
ECSP17055491A (es) Ácidos 3-alquil-4-amido-bicíclico [4,5,0] hidroxámico como inhibidores de hdac
CO2017001493A2 (es) Kits que comprenden inhibidores tigit y agentes anticáncer
AU201712054S (en) A Mask
MX2016006489A (es) Alfa-amilasas variantes que tienen susceptibilidad reducida a la escision por proteasas y metodos de uso.
CR20140586A (es) Celulas para producir iduronato-2-sulfatasa recombinante
CO2022017233A2 (es) 1-(5-(2-cianopiridin-4-il)oxazol-2-carbonil)-4-metilhexahidropirrolo[3,4-b]pirrol-5(1h)-carbonitrilo como inhibidor de usp30 para uso en el tratamiento de la disfunción mitocondrial, cáncer y fibrosis
MX2016000794A (es) Composiciones farmaceuticas de pancreatina de potencia alta.
CO7131352A2 (es) Composiciones farmacéuticas tópicas
UY4759S (es) Modelo industrial de cuerpo de extintor de incendios
MX2023002411A (es) Celulas inmunitarias modificadas para fibrosis e inflamacion.
UY37534A (es) Metodo para el tratamiento de enfermedades fibroticas utilizando el interferon-lambda
MX2016000480A (es) Composiciones farmaceuticas de pancreatina de alta potencia.
CO2022017112A2 (es) N-cianopirrolidinas con actividad como inhibidores de peptidasa específica de ubiquitina 30
CO2022014135A2 (es) Derivados de n-(1-ciano-pirrolidin-3-il)-5-(3-(trifluorometil)fenil)oxazol-2-carboxamida y los derivados oxadiazol correspondientes como inhibidores de usp30 para el tratamiento de disfunción mitocondrial
AU201814479S (en) A toothbrush
CL2019000429A1 (es) Conjugado de minoxidil y peptidos.
BR112014021326A2 (pt) célula para a expressão de protéina, método para reduzir a atividade de amidação de peptídeo em uma determinada célula, uso de uma célula
UY35695A (es) Composicion para el tratamiento contra el envejecimiento de la piel
PL409283A1 (pl) Enzym o wysokiej aktywności litycznej w stosunku do komórek Enterococcus oraz sposób modyfikacji jego genu pozwalający na nadprodukcję aktywnego enzymu w komórkach bakteryjnych
MX2020003745A (es) Planta fotovoltaica con estructura de soporte para panel.
CR20160116A (es) Método para tratar onicomicosis con hidroxipropil quitasano
AU201813581S (en) Tie
AU201813387S (en) Bus